Nuvectis Pharma, Inc. (NVCT)
NASDAQ: NVCT · Real-Time Price · USD
9.02
+0.13 (1.41%)
May 5, 2026, 10:07 AM EDT - Market open

Nuvectis Pharma Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-27.16-26.44-19-22.26-19.09-12.89
Stock-Based Compensation
6.516.034.864.711.711.89
Changes in Accounts Payable
1.73.78-0.27-0.141.851.59
Changes in Accrued Expenses
0.580.632.181.392.29-
Changes in Other Operating Activities
0.02-0-0.020.35-0.32-0.09
Operating Cash Flow
-18.35-16.01-12.25-15.95-13.56-9.5
Issuance of Common Stock
14.4231.2112.0416.4831.88-
Net Common Stock Issued (Repurchased)
14.4231.2112.0416.4831.88-
Issuance of Preferred Stock
-----15.25
Net Preferred Stock Issued (Repurchased)
-----15.25
Other Financing Activities
-0.81-2.1-0.38-1.39-4.07-
Financing Cash Flow
13.6129.1111.6515.0927.8115.25
Net Cash Flow
-4.7313.1-0.59-0.8714.255.74
Free Cash Flow
-18.35-16.01-12.25-15.95-13.56-9.5
Free Cash Flow Per Share
-0.81-0.73-0.72-1.03-1.07-2.23
Levered Free Cash Flow
-27.29-24.47-17.11-20.66-15.27-11.4
Unlevered Free Cash Flow
-25.97-23.17-17.95-21.3-15.42-11.4
Updated May 5, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q